Currently going for $4.37 apiece, Wall Street is pounding the table on this healthcare name.On August 31, the company announced that Mycapssa, the first and only oral somatostatin analog (SSA) approved as a long-term maintenance treatment for acromegaly patients who have responded to and tolerated octreotide or lanreotide (other approved therapies), had been launched one month ahead of guidance. All quotes are in local exchange time. Historical and current end-of-day data provided by FACTSET. Down 52% year-to-date, its $32.67 share price lands close to its $29.47 52-week low. The Notes and the related guarantees have not been and will not be registered under the Securities Act, or the securities laws of any state or other jurisdiction, and may not be offered or sold in the United States without registration or an applicable exemption from the registration requirements of the Securities Act and applicable state securities or blue sky laws and foreign securities laws. The Company upsized its offering of 2028 Notes by $100.0 million aggregate principal amount from the previously announced amount. )+[a-z]{2,63}/i);}, failureMessage: "Value must not contain any URL's"});field11.add(Validate.Presence, {failureMessage:"This field is required"});field11.add(Validate.Length, {tooShortMessage:"Invalid length for field value", tooLongMessage: "Invalid length for field value", minimum: 4, maximum: 4});function handleFormSubmit(ele) { var submitButton = ele.querySelector('input[type=submit]'); var spinner = document.createElement('span'); spinner.setAttribute('class', 'loader'); submitButton.setAttribute('disabled', true); = 'wait'; submitButton.parentNode.appendChild(spinner); return true; }function resetSubmitButton(e){ var submitButtons ='submit-button'); for(var i=0;i